NVNO

NVNO

USD

enVVeno Medical Corporation Common Stock

$2.735-0.031 (-1.121%)

Precio en Tiempo Real

Healthcare
Dispositivos médicos
Estados Unidos

Gráfico de Precios

Métricas Clave

Métricas de Mercado
Fundamentos de la Empresa
Estadísticas de Negociación

Métricas de Mercado

Apertura

$2.766

Máximo

$2.766

Mínimo

$2.660

Volumen

0.00M

Fundamentos de la Empresa

Capitalización de Mercado

48.0M

Industria

Dispositivos médicos

País

United States

Estadísticas de Negociación

Volumen Promedio

0.09M

Bolsa

NCM

Moneda

USD

Rango de 52 Semanas

Mínimo $2.028Actual $2.735Máximo $6.48

Noticias Relacionadas

AccessWire

Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand

- Access video webcasts from the first wave of participating companies hereFRENCHTOWN, NJ / ACCESS Newswire / February 19, 2025 / JTC Team , a fully integrated corporate communications and investor

Ver más
Virtual Investor "Top 5 for '25" Conference Hosted by JTC Now Available On-Demand
AccessWire

One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum

One-year follow-up data demonstrates sustained improvements across venous specific quality-of-life indicators.PMA application for the VenoValve submitted in November 2024, with an FDA decision expected in the

Ver más
One-Year Data from the VenoValve(R) U.S. Pivotal Trial Highlighting Impact on Patients' Quality of Life (QOL) to be Presented Today at the 37th Annual Meeting of the American Venous Forum
AccessWire

Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Two-year follow-up data from 34 subjects in the VenoValve pivotal trial show sustained clinical improvement and continued patient benefit, from 12 months to 24 months.78% of subjects maintained a clinically meaningful

Ver más
Interim Two-Year Follow-Up Data from the VenoValve(R) U.S. Pivotal Trial to be Presented Today at the VESS 2025 Annual Winter Meeting

Mantente Actualizado

Configura alertas de precio, recibe actualizaciones de análisis de IA y noticias de mercado en tiempo real.